|
|
 |
|
Viewing report
|
|
|
|
Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review
GlobalData, Feb 2012, Pages: 52
Valeant Pharmaceuticals International, Inc. (VRX) - Financial and Strategic SWOT Analysis Review
Summary
Valeant Pharmaceuticals International, Inc. (Valeant), formerly Biovail Corporation, is a specialty pharmaceutical company involved in developing, manufacturing and marketing of a wide range of specialty, over the counter and generic pharmaceutical products. The product portfolio of the company includes specialty pharmaceuticals across various therapeutic areas; over the counter drugs; and generic pharmaceuticals. Valeant operates through five business segments, namely, US Neurology and Other, US Dermatology, Canada and Australia, Branded Generics Europe, and Banded Generics Latin America. The company operates in US and Puerto Rico, Canada, Poland, Mexico, Brazil and Other geographies worldwide. Valeant is headquartered in Mississauga, Ontario, Canada.
The company focuses on expanding its offered product portfolio through both inorganic and organic approaches. Recently, the company completed the acquisitions of iNova, Dermik, and Ortho Dermatologics. The company also focuses acquiring dossiers and registrations for branded generic products, which require limited manufacturing start-up and development activities.
Valeant Pharmaceuticals International, Inc. Key Recent Developments
Feb 27, 2012: Valeant Pharmaceuticals Reports Revenue Of $688.5m Q4 2011 Results
Nov 10, 2011: Valeant Pharmaceuticals Appoints Howard B Schiller As CFO
Nov 03, 2011: Valeant Pharmaceuticals Reports Revenue Of $600.6m Q3 2011 Results
Aug 18, 2011: Valeant Announces Resignation Of Michael Van Every From Board
Aug 04, 2011: Valeant Pharmaceuticals Reports Total Revenue Of $609.4m For Q2 2011
This comprehensive SWOT profile of Valeant Pharmaceuticals International, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Key Words
Valeant Pharmaceuticals International, Inc., SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History, Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts
Customers who bought this item also bought
Hikma Pharmaceuticals PLC (HIK) - Financial and Strategic SWOT Analysis Review
Hospira, Inc. (HSP) - Financial and Strategic SWOT Analysis Review
Watson Pharmaceuticals, Inc. (WPI) - Financial and Strategic SWOT Analysis Review
Alexza Pharmaceuticals, Inc. (ALXA) - Financial and Strategic SWOT Analysis Review
Mundipharma International Limited - Strategic SWOT Analysis Review
Par Pharmaceutical Companies, Inc. (PRX) - Financial and Strategic SWOT Analysis Review
GlaxoSmithKline plc (GSK) - Financial and Strategic SWOT Analysis Review
Transdel Pharmaceuticals, Inc. (TDLPD) - Financial and Strategic SWOT Analysis Review
Stereotaxis, Inc. (STXS) - Financial and Strategic SWOT Analysis Review
Aptalis Pharma Inc. - Strategic SWOT Analysis Review
|
|
|
|
